Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

KRX:007570 Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	276,352	268,861	266,669	247,773	242,511	343,329
Other Revenue	-	-	-0	-0	-0	-
Revenue	276,352	268,861	266,669	247,773	242,511	343,329
Revenue Growth (YoY)	26.66%	0.82%	7.63%	2.17%	-29.37%	5.78%
Cost of Revenue	160,471	157,461	150,265	139,579	137,865	161,690
Gross Profit	115,881	111,401	116,404	108,194	104,646	181,638
Selling, General & Admin	75,512	72,712	73,605	69,591	69,145	124,701
Research & Development	25,018	24,740	23,748	22,395	16,829	19,723
Other Operating Expenses	1,984	1,967	1,954	1,832	1,764	1,944
Operating Expenses	103,495	100,400	100,024	93,945	89,458	147,538
Operating Income	12,386	11,000	16,379	14,249	15,188	34,101
Interest Expense	-3,051	-2,932	-3,225	-2,132	-1,894	-3,017
Interest & Investment Income	531.03	619.4	361.43	279.06	348.43	516.99
Earnings From Equity Investments	1,992	2,083	-13,425	10,754	9,236	-
Currency Exchange Gain (Loss)	-80.31	1,222	-1,011	-551.53	1,265	-918.59
Other Non Operating Income (Expenses)	392.58	263.21	-928.6	1,288	-2,347	-354.03
EBT Excluding Unusual Items	12,171	12,256	-1,849	23,887	21,797	30,329
Gain (Loss) on Sale of Investments	20.81	27.78	8.92	-24.78	-	-123.55
Gain (Loss) on Sale of Assets	9.37	-8.96	0.53	21.22	2.86	134.47
Asset Writedown	6.65	2.15	40.51	-36.82	263.19	-1,947
Pretax Income	12,207	12,277	-1,799	23,846	22,063	28,393
Income Tax Expense	511.93	1,770	230.97	4,040	7,311	6,847
Earnings From Continuing Operations	11,696	10,508	-2,030	19,806	14,752	21,545
Minority Interest in Earnings	-238.71	-250.39	-378.26	-420.96	-719.83	-10,666
Net Income	11,457	10,257	-2,409	19,385	14,032	10,880
Preferred Dividends & Other Adjustments	518.25	489.25	-44.02	449.28	-	-
Net Income to Common	10,939	9,768	-2,365	18,936	14,032	10,880
Net Income Growth	2168.90%	-	-	38.15%	28.98%	8.96%
Shares Outstanding (Basic)	18	18	18	18	18	18
Shares Outstanding (Diluted)	18	18	18	18	18	18
Shares Change (YoY)	-0.03%	-0.26%	-0.59%	-0.44%	-	-
EPS (Basic)	608.86	543.53	-131.23	1044.71	770.78	597.61
EPS (Diluted)	608.86	543.53	-131.23	1036.00	770.78	597.00
EPS Growth	2360.27%	-	-	34.41%	29.11%	8.94%
Free Cash Flow	-31,994	-32,585	8,736	1,938	39,057	47,310
Free Cash Flow Per Share	-1780.85	-1813.13	484.85	106.90	2145.40	2598.70
Dividend Per Share	150.000	150.000	-	-	-	-
Gross Margin	41.93%	41.43%	43.65%	43.67%	43.15%	52.91%
Operating Margin	4.48%	4.09%	6.14%	5.75%	6.26%	9.93%
Profit Margin	3.96%	3.63%	-0.89%	7.64%	5.79%	3.17%
Free Cash Flow Margin	-11.58%	-12.12%	3.28%	0.78%	16.11%	13.78%
EBITDA	21,343	20,824	28,350	26,016	26,415	46,765
EBITDA Margin	7.72%	7.75%	10.63%	10.50%	10.89%	13.62%
D&A For EBITDA	8,957	9,824	11,971	11,767	11,227	12,664
EBIT	12,386	11,000	16,379	14,249	15,188	34,101
EBIT Margin	4.48%	4.09%	6.14%	5.75%	6.26%	9.93%
Effective Tax Rate	4.19%	14.41%	-	16.94%	33.14%	24.12%
Advertising Expenses	-	6,409	6,264	6,312	7,205	35,608

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.